Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients
Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 17(2021), 7 vom: 05. März, Seite 807-815 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caffo, Orazio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.10.2021 Date Revised 01.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2020-0391 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320705765 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320705765 | ||
| 003 | DE-627 | ||
| 005 | 20231225174140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2020-0391 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320705765 | ||
| 035 | |a (NLM)33508980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caffo, Orazio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.10.2021 | ||
| 500 | |a Date Revised 01.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a metastatic castration-resistant prostate cancer | |
| 650 | 4 | |a prognostic factors | |
| 650 | 4 | |a radium 223 | |
| 650 | 4 | |a sequencing | |
| 650 | 7 | |a Androgen Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Radium-223 |2 NLM | |
| 650 | 7 | |a 8BR2SOL3L1 |2 NLM | |
| 650 | 7 | |a Radium |2 NLM | |
| 650 | 7 | |a W90AYD6R3Q |2 NLM | |
| 700 | 1 | |a Frantellizzi, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Monari, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Sbrana, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Renato Patrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Tucci, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Baldari, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Facchini, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Bortolus, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Alongi, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Alongi, Pierpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Palermo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Fanti, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Biasco, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Murabito, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Filice, Angelina |e verfasserin |4 aut | |
| 700 | 1 | |a Zichi, Clizia |e verfasserin |4 aut | |
| 700 | 1 | |a Pignata, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Borsatti, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Salgarello, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Spada, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Cortesi, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Vincentis, Giuseppe De |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 17(2021), 7 vom: 05. März, Seite 807-815 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:7 |g day:05 |g month:03 |g pages:807-815 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2020-0391 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 7 |b 05 |c 03 |h 807-815 | ||